Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2025Journal of Clinical Obstetrics and Gynecology Research

Treatment Of Advanced Endometrial Cancer: A Systematic Review Of Efficacy And Safety In Clinical Trials, Molecular-Targeted Therapies And Immunotherapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

LPL. PinheiroTAThalita Pinheiro Morel AlineriHMHadassa Alcantu de Mauro

Discussion

Loading...

Member takes

Overview

Systematic review demonstrates improved overall survival with molecular-targeted therapies and immunotherapy in advanced endometrial cancer, suggesting a need for personalized treatment.

Key Points

  • Advanced endometrial cancer management is challenging but sees promise from molecular-targeted therapies and immunotherapy.
  • Estimates show that mTOR inhibitors and antiangiogenic drugs achieve objective response rates between 10% and 20%.
  • Immunotherapy with pembrolizumab demonstrated high efficacy with an objective response rate above 45% in patients with microsatellite instability.
  • Personalized treatment strategies based on molecular biomarkers can potentially improve clinical outcomes in endometrial cancer.

Cite This Study

Pinheiro et al. (2025) studied this question.

synapsesocial.com/papers/689a02b6e6551bb0af8cc1e2https://doi.org/10.52338/jocogr.2025.4937
View Full Paper
Ask AI
Bookmark
Share